Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Articles published by AstraZeneca

< Previous 1 2 3 4 5 6 7 8 9 Next >

AstraZeneca advances UK clean heat and energy efficiencies with £100m commitment

September 14, 2023

From AstraZeneca

Via Business Wire

FASENRA met the primary endpoint in the MANDARA Phase III trial in eosinophilic granulomatosis with polyangiitis (EGPA)

September 11, 2023

From AstraZeneca

Via Business Wire

TAGRISSO® (osimertinib) Plus Chemotherapy Extended Median Progression-free Survival by Nearly 9 Months in EGFR-mutated Advanced Lung Cancer in FLAURA2 Phase III Trial

September 11, 2023

From AstraZeneca

Via Business Wire

ENHERTU® (fam-trastuzumab deruxtecan-nxki) Demonstrated Strong and Durable Tumor Responses in Previously Treated HER2-mutant Advanced Lung Cancer in DESTINY-Lung02 Phase II Trial

September 11, 2023

From AstraZeneca

Via Business Wire

AstraZeneca urges re-examination of unintended consequences of Inflation Reduction Act on American cancer and rare disease patients

August 25, 2023

From AstraZeneca

Via Business Wire

AstraZeneca Data at WCLC Advance Ambition to Have an AstraZeneca Medicine for More Than Half of All Patients Treated for Lung Cancer by 2030

August 16, 2023

From AstraZeneca

Via Business Wire

ENHERTU® (fam-trastuzumab deruxtecan-nxki) Demonstrated Clinically Meaningful Progression-Free Survival and Overall Survival Across Multiple HER2-Expressing Advanced Solid Tumors in DESTINY-PanTumor02 Phase II Trial

July 27, 2023

From AstraZeneca

Via Business Wire

Datopotamab Deruxtecan Met Dual Primary Endpoint of Progression-Free Survival in Patients With Advanced Non-Small Cell Lung Cancer in TROPION-Lung01 Phase III Trial

July 03, 2023

From AstraZeneca

Via Business Wire

IMFINZI® (durvalumab) plus IMJUDO® (tremelimumab-actl) demonstrated sustained overall survival benefit in advanced liver cancer with an unprecedented one in four patients alive at four years in HIMALAYA Phase III trial

June 29, 2023

From AstraZeneca

Via Business Wire

AstraZeneca announces $400 million investment in reforestation and biodiversity in support of climate action and human health

June 28, 2023

From AstraZeneca

Via Business Wire

AstraZeneca announces innovative partnership with Vanguard Renewables to decarbonize its United States sites

June 13, 2023

From AstraZeneca

Via Business Wire

Capivasertib in combination with FASLODEX® (fulvestrant) granted Priority Review in the US for patients with advanced HR-positive breast cancer

June 12, 2023

From AstraZeneca

Via Business Wire

Datopotamab deruxtecan combinations showed encouraging tumor responses in patients with advanced non-small cell lung cancer in TROPION-Lung02 Phase Ib trial

June 05, 2023

From AstraZeneca

Via Business Wire

ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated clinically meaningful and durable responses in patients across multiple HER2-expressing advanced solid tumors

June 05, 2023

From AstraZeneca

Via Business Wire

ANDEXXA Phase IV Trial Stopped Early After Achieving Pre-specified Criteria on Hemostatic Efficacy Versus Usual Care

June 05, 2023

From AstraZeneca

Via Business Wire

TAGRISSO® achieved unprecedented survival in early-stage EGFR-mutated lung cancer, with 88% of patients alive at five years in ADAURA Phase III trial

June 04, 2023

From AstraZeneca

Via Business Wire

LYNPARZA® (olaparib) and IMFINZI® (durvalumab) combination reduced risk of disease progression or death by 37% vs. chemotherapy and bevacizumab in patients with advanced ovarian cancer without tumor BRCA mutations in the DUO-O Phase III trial

June 03, 2023

From AstraZeneca

Via Business Wire

IMFINZI® (durvalumab) plus chemotherapy significantly improved pathologic complete response in gastric and gastroesophageal junction cancers in MATTERHORN Phase III trial

June 02, 2023

From AstraZeneca

Via Business Wire

LYNPARZA® (olaparib) plus abiraterone approved in the US for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer

June 01, 2023

From AstraZeneca

Via Business Wire

IMFINZI® (durvalumab) plus LYNPARZA® (olaparib) and IMFINZI alone both significantly improved progression-free survival in advanced endometrial cancer when added to chemotherapy

May 26, 2023

From AstraZeneca

Via Business Wire

AstraZeneca will highlight momentum of practice-changing cancer medicines across its robust pipeline at ASCO 2023

May 25, 2023

From AstraZeneca

Via Business Wire

New AstraZeneca Data Presented at ATS 2023 Strengthen the Body of Evidence Supporting Early Intervention With BREZTRI in COPD

May 23, 2023

From AstraZeneca

Via Business Wire

TAGRISSO® (osimertinib) plus chemotherapy demonstrated strong improvement in progression-free survival for patients with EGFR-mutated advanced lung cancer in FLAURA2 Phase III trial

May 17, 2023

From AstraZeneca

Via Business Wire

FARXIGA extended in the US to reduce risk of cardiovascular death and hospitalization for heart failure to a broader range of patients

May 09, 2023

From AstraZeneca

Via Business Wire

NEURO-TTRansform Phase III results presented at AAN showed eplontersen demonstrated consistent and sustained improvement in all measures of disease and quality of life through 66 weeks

April 24, 2023

From AstraZeneca

Via Business Wire

IMFINZI-based treatment before and after surgery reduced the risk of disease recurrence, progression events or death by 32% in resectable non-small cell lung cancer in the AEGEAN Phase III trial

April 16, 2023

From AstraZeneca

Via Business Wire

AstraZeneca reinforces commitment to advancing science for patients with chronic kidney disease and hyperkalemia at NKF Spring Clinical Meeting 2023

April 11, 2023

From AstraZeneca

Via Business Wire

Eplontersen demonstrated sustained benefit in Phase III trial for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) through 66 weeks

March 27, 2023

From AstraZeneca

Via Business Wire

TAGRISSO® (osimertinib) demonstrated strong overall survival benefit in the ADAURA Phase III trial for adjuvant treatment of patients with early-stage EGFR-mutated lung cancer

March 09, 2023

From AstraZeneca

Via Business Wire

IMFINZI significantly improved event-free survival in AEGEAN Phase III trial for patients with resectable non-small cell lung cancer

March 09, 2023

From AstraZeneca

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.